|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LUC7L3 |
Gene summary for LUC7L3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LUC7L3 | Gene ID | 51747 |
| Gene name | LUC7 like 3 pre-mRNA splicing factor | |
| Gene Alias | CRA | |
| Cytomap | 17q21.33 | |
| Gene Type | protein-coding | GO ID | GO:0000245 | UniProtAcc | J3KPP4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51747 | LUC7L3 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 2.24e-15 | 7.83e-01 | -0.23 |
| 51747 | LUC7L3 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 2.12e-24 | 1.08e+00 | -0.23 |
| 51747 | LUC7L3 | 047563_1562-all-cells | Human | Prostate | BPH | 4.16e-18 | 2.81e-03 | 0.0791 |
| 51747 | LUC7L3 | 048752_1579-all-cells | Human | Prostate | BPH | 9.12e-06 | 2.96e-01 | 0.1008 |
| 51747 | LUC7L3 | 052095_1628-all-cells | Human | Prostate | BPH | 1.13e-03 | 3.34e-01 | 0.1032 |
| 51747 | LUC7L3 | 052097_1595-all-cells | Human | Prostate | BPH | 3.18e-02 | 3.06e-01 | 0.0972 |
| 51747 | LUC7L3 | 052099_1652-all-cells | Human | Prostate | BPH | 8.83e-04 | 3.55e-01 | 0.1038 |
| 51747 | LUC7L3 | Dong_P1 | Human | Prostate | Tumor | 4.13e-29 | -2.55e-02 | 0.035 |
| 51747 | LUC7L3 | Dong_P3 | Human | Prostate | Tumor | 3.95e-12 | 2.50e-01 | 0.0278 |
| 51747 | LUC7L3 | Dong_P4 | Human | Prostate | Tumor | 1.04e-06 | 2.38e-01 | 0.0292 |
| 51747 | LUC7L3 | Dong_P5 | Human | Prostate | Tumor | 1.48e-24 | 1.30e-01 | 0.053 |
| 51747 | LUC7L3 | P7 | Human | Prostate | Tumor | 4.20e-09 | 9.07e-01 | -0.1025 |
| 51747 | LUC7L3 | P10 | Human | Prostate | Tumor | 6.99e-04 | 4.29e-01 | -0.0902 |
| 51747 | LUC7L3 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.16e-03 | 3.16e-01 | 0.1608 |
| 51747 | LUC7L3 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 7.67e-05 | 4.62e-01 | 0.1604 |
| 51747 | LUC7L3 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 2.69e-07 | 6.07e-01 | 0.1621 |
| 51747 | LUC7L3 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.74e-04 | -7.75e-02 | 0.1602 |
| 51747 | LUC7L3 | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 9.59e-10 | 2.23e-01 | 0.1439 |
| 51747 | LUC7L3 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 9.03e-03 | 8.52e-02 | 0.1608 |
| 51747 | LUC7L3 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 4.20e-03 | -1.32e-02 | 0.1575 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
| GO:00718269 | Breast | Precancer | ribonucleoprotein complex subunit organization | 48/1080 | 227/18723 | 2.68e-15 | 8.45e-13 | 48 |
| GO:00226189 | Breast | Precancer | ribonucleoprotein complex assembly | 47/1080 | 220/18723 | 3.47e-15 | 1.03e-12 | 47 |
| GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
| GO:00003759 | Breast | Precancer | RNA splicing, via transesterification reactions | 52/1080 | 324/18723 | 1.74e-11 | 2.22e-09 | 52 |
| GO:00003779 | Breast | Precancer | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
| GO:00003989 | Breast | Precancer | mRNA splicing, via spliceosome | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
| GO:002261314 | Breast | IDC | ribonucleoprotein complex biogenesis | 83/1434 | 463/18723 | 2.01e-13 | 5.20e-11 | 83 |
| GO:007182614 | Breast | IDC | ribonucleoprotein complex subunit organization | 52/1434 | 227/18723 | 5.18e-13 | 1.21e-10 | 52 |
| GO:002261814 | Breast | IDC | ribonucleoprotein complex assembly | 51/1434 | 220/18723 | 5.32e-13 | 1.21e-10 | 51 |
| GO:000838014 | Breast | IDC | RNA splicing | 73/1434 | 434/18723 | 1.27e-10 | 1.57e-08 | 73 |
| GO:000037514 | Breast | IDC | RNA splicing, via transesterification reactions | 58/1434 | 324/18723 | 9.44e-10 | 9.58e-08 | 58 |
| GO:000037714 | Breast | IDC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
| GO:000039814 | Breast | IDC | mRNA splicing, via spliceosome | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
| GO:002261324 | Breast | DCIS | ribonucleoprotein complex biogenesis | 83/1390 | 463/18723 | 3.65e-14 | 1.09e-11 | 83 |
| GO:007182624 | Breast | DCIS | ribonucleoprotein complex subunit organization | 52/1390 | 227/18723 | 1.54e-13 | 3.95e-11 | 52 |
| GO:002261824 | Breast | DCIS | ribonucleoprotein complex assembly | 51/1390 | 220/18723 | 1.60e-13 | 3.95e-11 | 51 |
| GO:000838024 | Breast | DCIS | RNA splicing | 73/1390 | 434/18723 | 3.05e-11 | 5.08e-09 | 73 |
| GO:000037524 | Breast | DCIS | RNA splicing, via transesterification reactions | 58/1390 | 324/18723 | 2.89e-10 | 3.34e-08 | 58 |
| GO:000037724 | Breast | DCIS | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1390 | 320/18723 | 5.01e-10 | 5.35e-08 | 57 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LUC7L3 | SNV | Missense_Mutation | c.685N>C | p.Glu229Gln | p.E229Q | protein_coding | tolerated(0.06) | benign(0.293) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| LUC7L3 | SNV | Missense_Mutation | novel | c.1178N>T | p.Ser393Phe | p.S393F | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| LUC7L3 | SNV | Missense_Mutation | c.620G>A | p.Arg207Gln | p.R207Q | protein_coding | deleterious(0.04) | probably_damaging(0.979) | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| LUC7L3 | deletion | Frame_Shift_Del | c.228delC | p.Phe76LeufsTer2 | p.F76Lfs*2 | protein_coding | TCGA-E9-A248-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||||
| LUC7L3 | SNV | Missense_Mutation | novel | c.1361N>A | p.Ser454Asn | p.S454N | protein_coding | tolerated_low_confidence(0.18) | probably_damaging(0.995) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| LUC7L3 | SNV | Missense_Mutation | c.607G>A | p.Asp203Asn | p.D203N | protein_coding | deleterious(0) | benign(0.019) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| LUC7L3 | SNV | Missense_Mutation | c.781N>T | p.Arg261Trp | p.R261W | protein_coding | deleterious(0) | possibly_damaging(0.645) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| LUC7L3 | SNV | Missense_Mutation | c.781C>T | p.Arg261Trp | p.R261W | protein_coding | deleterious(0) | possibly_damaging(0.645) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| LUC7L3 | SNV | Missense_Mutation | novel | c.107N>C | p.Lys36Thr | p.K36T | protein_coding | tolerated(0.31) | possibly_damaging(0.482) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| LUC7L3 | SNV | Missense_Mutation | c.530N>T | p.Ser177Leu | p.S177L | protein_coding | tolerated(0.13) | probably_damaging(0.979) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |